Myria Biosciences

High-Level Overview

Myria Biosciences AG is a Basel-based biotechnology company founded in 2021-2022 that develops the GEMMS (Genetically Engineered Modular Molecule Scaffolds) platform, combining synthetic biology, artificial intelligence, and high-throughput screening to design, produce, and test millions of novel therapeutic compounds inspired by natural products.[1][2][4][5] It serves pharmaceutical companies and addresses unmet medical needs by targeting previously undruggable diseases through biologically engineered molecules at unprecedented speed—millions per week—unlocking chemical space beyond natural evolution.[2][3][4] The company recently closed a pre-seed funding round to expand its team, launch an internal drug pipeline, and form pharma partnerships, positioning it among AI-driven drug discovery startups with a unique SynBio edge.[2][4]

Origin Story

Myria Biosciences emerged as a spin-off from ETH Zurich's D-BSSE Bioprocess Lab (led by Sven Panke), integrating science from ETH Zurich, the Max Planck Institute, and the Helmholtz Institute for Pharmaceutical Research Saarland.[2][4] Founded in 2021 (with formal incorporation noted in 2022), it was established by CEO Dr. Steven Schmitt (D-BSSE alumnus), CSO Kenan Bozhüyük, and COO Irene Wüthrich, leveraging their expertise in synthetic biology and AI to pioneer "synthetic intelligence" for drug development.[1][2][4] Early traction came from the GEMMS platform's ability to genetically engineer cells for novel compounds, culminating in the pre-seed announcement that validates its potential to disrupt traditional drug discovery.[2][4]

Core Differentiators

• Synthetic Intelligence Platform (GEMMS): Merges AI-driven design, synthetic biology for biological production, and high-throughput testing to generate and optimize millions of natural product-inspired molecules weekly, surpassing nature's evolutionary limits.[1][2][4][5]
• Access to New Chemical Space: Targets undruggable diseases by engineering complex scaffolds biologically, enabling data-driven candidates for challenging targets with precision and speed.[2][3][4]
• Proven Scientific Pedigree: Backed by IP from top institutions (ETH Zurich, Max Planck, Helmholtz), with a small team (1-10 employees) focused on biotech and IT innovation.[1][2][4]
• Scalable Production and Testing: Uses computational mining and engineered microbes for rapid iteration, differentiating from pure AI or chemical synthesis approaches.[5][6]

Role in the Broader Tech Landscape

Myria rides the convergence of AI advancements and synthetic biology in drug discovery, a trend accelerating since 2023 with startups disrupting pharma's high failure rates and long timelines.[2][4] Timing aligns with post-pandemic biotech investment recovery and AI's maturation for molecular design, amplified by SynBio's ability to produce testable compounds at scale amid rising demand for precision therapies.[2][6] Market forces like pharma's need for novel antibiotics, oncology drugs, and rare disease treatments favor Myria, as traditional small-molecule libraries exhaust viable options.[1][3] It influences the ecosystem by partnering with big pharma, expanding accessible chemical space, and inspiring hybrid AI-SynBio models that could shorten development from years to months.[2][4]

Quick Take & Future Outlook

Myria is poised to scale its GEMMS platform with pre-seed funds, prioritizing team growth, internal pipelines for high-need targets, and pharma alliances to validate hits.[2][4] Trends like multimodal AI integration and automated SynBio foundries will amplify its edge, potentially yielding first clinical candidates by 2027-2028 if partnerships accelerate. Its influence may evolve from pioneer to category leader, redefining drug discovery by making "synthetic intelligence" the standard for undruggable targets—transforming Basel's biotech hub and proving AI x SynBio unlocks therapies nature overlooked.[2][6]